- Pentavere Research Group, a subsidiary of Healwell AI (TSX:AIDX), is announcing its collaboration with Princess Margaret Cancer Centre that expedited the detection of radiation-related toxicity in cancer patients has been accepted at two medical conferences
- The partners used Pentavere’s DARWEN AI system, an AI engine to identify patients who are eligible for a given medication or intervention, to locate patients experiencing radiation toxicity using electronic health records
- Healwell AI is a healthcare technology company applying AI and data science to preventative care
- Healwell AI stock is up by 1,311.11 per cent year-over-year but remains down by 44.78 per cent since inception in 2021
Pentavere Research Group, a subsidiary of Healwell AI (TSX:AIDX), is announcing its collaboration with Princess Margaret Cancer Centre that expedited the detection of radiation-related toxicity in cancer patients has been accepted at two medical conferences:
- The Canadian Association of Radiation Oncology on Sept. 11 in Vancouver.
- The American Society for Radiation Oncology on Sept. 29 in Washington, D.C.
The partners used Pentavere‘s DARWEN AI system, an AI engine to identify patients that are eligible for a given medication or intervention, to locate patients experiencing radiation toxicity using electronic health records.
About half of all cancer patients undergo radiation therapy, and approximately 10 per cent of them will experience severe toxicity, decreasing survival and quality of life, making the early identification of radiation toxicity a significant unmet need. To this end, The Adult Radiation Late Effect Clinic (ARLEC) at Princess Margaret Cancer Centre – the only clinic of its kind in Canada established for patients with radiotherapy side effects – is partnering with Healwell AI to compile the data required to identify and do research on these patients.
The news complements Pentavere’s previously published work showing DARWEN AI supported physicians to enhance cancer staging and improve patient outcomes.
Leadership insights
“We continually hear from clinicians, scientists and policy makers the paramount importance in building trust through peer-reviewed validation to unlock the potential of AI in healthcare,” Aaron Leibtag, Pentavere’s co-founder and chief executive officer, said in a statement. “We are grateful to Dr. Wong and ARLEC at Princess Margaret Cancer Centre for partnering with Pentavere to build this trust together. This successful collaboration is further evidence demonstrating the power of AI to identify patients, detect disease and support clinicians by accelerating the time-to-discovery of clinical insights buried in electronic health records. This is another step forward in our mission to support clinicians so that they can provide the best care to their patients.”
“Early identification of these patients is critical to improve outcomes, but frequently they get missed or their referral delayed,” added Dr. Philip Wong, Radiation Oncologist at Princess Margaret Cancer Centre. “This study demonstrated that with Pentavere’s AI we can explore our entire cancer population in a way we’ve never done before and accelerate our ability to intervene early with multidisciplinary preventative care to improve outcomes and preserve patient quality of life.”
About Healwell AI
Healwell is a healthcare technology company applying AI and data science to preventative care.
Healwell AI stock (TSX:AIDX) is up by 10.92 per cent, trading at C$2.54 per share as of 10:44 am ET. The stock is up by 1,311.11 per cent year-over-year, but remains down by 44.78 per cent since inception in 2021.
Join the discussion: Find out what everybody’s saying about cancer research and this healthcare AI stock on the Healwell AI Inc. Bullboard, and check out Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
(Top photo, generated by AI: Adobe Stock)